business / news / / The Motley Fool Australia
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today.
Telix and Regeneron entered a 50/50 global cost and profit-sharing agreement for radiopharmaceutical therapies.
KEY POINTS
- Telix receives a US$40 million upfront payment for four initial programs, with expansion options.
- The deal could yield up to US$2.1 billion in milestone payments plus royalties for Telix.
- Telix will lead commercialisation of diagnostic assets, with Regeneron receiving a share of profits.
COMPANIES
Summarized by Newsio from The Motley Fool Australia. How we summarize →